Pier Maria Fornasari: Possible New Target for SCD and Beta Thalassemia Treatment
Pier Maria Fornasari, Director of Regenhealthsolutions.info, shared a post on LinkedIn:
“Possible New Target for Sickle Cell Disease and Beta Thalassemia Treatment identified by Harvard Medical School Researchers
BACH2 regulates HbF independently of BCL11A
Researchers identify additional gene controlling production of fetal hemoglobin
Harvard Medical School researchers at Boston Children’s Hospital and Dana-Farber Cancer Institute have identified a new pathway that regulates the production of fetal hemoglobin, a form of hemoglobin that normally gets replaced soon after birth by adult hemoglobin.
Two FDA-approved gene therapies reactivate the production of fetal hemoglobin as a treatment for sickle cell disease and beta thalassemia, which are caused by mutations in adult hemoglobin….”
Stay updated with Hemostasis Today.
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C
-
Nov 16, 2026, 12:52Frank Nocken: Alzheimer’s Research Expands Beyond Amyloid-Based Treatments